A Study of Galcanezumab in Participants With Chronic Cluster Headache

NCT02438826 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Cluster Headache

Interventions

DRUG: Galcanezumab 300 mg
DRUG: Placebo

Sponsor

Eli Lilly and Company